Dalpiciclib
- Generic Name
- Dalpiciclib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30N6O2
- CAS Number
- 1637781-04-4
- Unique Ingredient Identifier
- 5ZHA5P4PFX
- Associated Conditions
- -
- Associated Therapies
- -
Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC
- Conditions
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 52
- Registration Number
- NCT06711094
Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Peking University
- Target Recruit Count
- 100
- Registration Number
- NCT06650748
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06613373
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Lead Sponsor
- Zhimin Shao
- Target Recruit Count
- 307
- Registration Number
- NCT06612814
- Locations
- 🇨🇳
breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Exploration of Dalpiciclib + Tucidinostat in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 155
- Registration Number
- NCT06556862
- Locations
- 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06552858
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-04-02
- Target Recruit Count
- 1163
- Registration Number
- NCT06341894
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Dalpiciclib in HR+/HER2- ABC
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 103
- Registration Number
- NCT06301438
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT06149130
- Locations
- 🇨🇳
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT06107673
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.